tert-Butyl 4-(2-aminopyridin-4-yl)piperazine-1-carboxylate

Catalog No. :
ACBEGS613
CAS No. :
571189-23-6
Molecular Formula :
C14H22N4O2
Molecular Weight :
278.36

IUPAC Name:tert-butyl 4-(2-aminopyridin-4-yl)piperazine-1-carboxylate

tert-Butyl 4-(2-aminopyridin-4-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$82.00Login to see priceIn stockIn stock
1g95%$215.00Login to see priceIn stockIn stock
5g95%$795.00Login to see priceIn stockInquiry
25g95%$2957.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(2-aminopyridin-4-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(2-aminopyridin-4-yl)piperazine-1-carboxylate
MDL No.MFCD11849292
Molecular FormulaC14H22N4O2
Molecular Weight278.36
SMILESO=C(OC(C)(C)C)N1CCN(C2C=CN=C(N)C=2)CC1
InChI KeyICNBTOYLGTVUCE-UHFFFAOYSA-N
Synonym1-BOC-4-(2-AMINO-4-PYRIDINYL)-PIPERAZINE;tert-butyl 4-(2-aminopyridin-4-yl)piperazine-1-carboxylate;TERT-BUTYL 4-(2-AMINOPYRIDIN-4-YL)PIPERAZINE-1-CARBOXYLATE(WX160252);4-(4-Boc-1-piperazinyl)pyridin-2-amine;1-Piperazinecarboxylic acid, 4-(2-amino-4-pyridinyl)-, 1,1-dimethylethyl ester;Bucillamine Impurity 5;Palbociclib Impurity 110
CAS No.571189-23-6
PubChem CID75481723

Synthetic Route by SureRoute

1. ACBEGS613 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACLTZU019 route compound structure diagram
    ACLTZU01984249-14-9 In Stock
  4. Then
  5. ACBEGS613 route product structure diagram
    ACBEGS613571189-23-6 In Stock
Inquiry

2. ACBEGS613 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBEGS613 route product structure diagram
    ACBEGS613571189-23-6 In Stock
Inquiry

Comments (0)